1. Home
  2. NXTC vs BRLT Comparison

NXTC vs BRLT Comparison

Compare NXTC & BRLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextCure Inc.

NXTC

NextCure Inc.

SELL

Current Price

$6.83

Market Cap

24.8M

Sector

Health Care

ML Signal

SELL

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

SELL

Current Price

$1.17

Market Cap

25.5M

ML Signal

SELL

Company Overview

Basic Information
Metric
NXTC
BRLT
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
25.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
NXTC
BRLT
Price
$6.83
$1.17
Analyst Decision
Strong Buy
Hold
Analyst Count
3
4
Target Price
★ $20.00
$1.63
AVG Volume (30 Days)
51.7K
★ 62.1K
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
$22,378,000.00
★ $437,483,000.00
Revenue This Year
N/A
$5.10
Revenue Next Year
N/A
$5.13
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3.63
52 Week Low
$1.55
$1.00
52 Week High
$15.74
$2.06

Technical Indicators

Market Signals
Indicator
NXTC
BRLT
Relative Strength Index (RSI) 54.35 27.78
Support Level $4.28 $1.09
Resistance Level $6.66 $1.30
Average True Range (ATR) 0.80 0.11
MACD 0.09 -0.04
Stochastic Oscillator 69.35 13.13

Price Performance

Historical Comparison
NXTC
BRLT

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

Share on Social Networks: